Indivior PLC (LON:INDV – Get Free Report) insider Jo Le Couilliard bought 1,490 shares of the stock in a transaction that occurred on Friday, July 26th. The stock was acquired at an average cost of GBX 1,006 ($13.01) per share, for a total transaction of £14,989.40 ($19,386.19).
Indivior Price Performance
Shares of INDV stock traded up GBX 25.50 ($0.33) during trading hours on Friday, reaching GBX 987 ($12.77). 971,842 shares of the company were exchanged, compared to its average volume of 562,394. Indivior PLC has a fifty-two week low of GBX 653 ($8.45) and a fifty-two week high of GBX 1,927 ($24.92). The stock’s fifty day moving average is GBX 1,179.64 and its two-hundred day moving average is GBX 1,386.36. The company has a market cap of £1.33 billion, a price-to-earnings ratio of 32,050.00, a P/E/G ratio of -5.57 and a beta of 0.06. The company has a debt-to-equity ratio of 2,790.00, a current ratio of 0.93 and a quick ratio of 1.52.
Analysts Set New Price Targets
Separately, Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Indivior from GBX 2,350 ($30.39) to GBX 1,500 ($19.40) and set a “buy” rating on the stock in a research note on Tuesday, July 9th.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- Best Aerospace Stocks Investing
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Investing in Construction Stocks
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.